Annals of Oncology Advance Access originally published online on January 19, 2005
Annals of Oncology 2005 16(3):411-418; doi:10.1093/annonc/mdi087
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial
Fédération Nationale des Centres de Lutte Contre le Cancer, 101 rue de Tolbiac, 75 013 Paris, France
Departments of Medical Oncology, 1Hôpital Tenon, Paris, 2 Institut Bergonié, Bordeaux, 4 Institut Gustave Roussy, Villejuif, 5 Centre Oscar Lambret, Lille, 6 Institut Paoli-Calmette, Marseille, 7 Centre Paul Papin, Angers, 8 Centre François Baclesse, Caen, 9 Centre Paul Strauss, Strasbourg, 10 Hôpital d'Instruction des Armées, Clamart, 11 Centre Jean Perrin, Clermont-Ferrand, 12 Centre Léon Bérard, Lyon, 13 Centre Val d'Aurelle, Montpellier; 3 Biostatistical Unit, Centre Léon Bérard, Lyon, France
* Correspondence to: Professor J.-P. Lotz, Hôpital Tenon, Assistance Publique—Hôpitaux de Paris, 4 rue de Chine, 75 970 Paris cedex 20, France. Tel: +33-1-56-01-60-58; Fax: +33-1-56-01-68-75; Email: jean-pierre.lotz{at}tnn.ap-hop-paris.fr
Background: High-dose chemotherapy (HD-CT) is able to circumvent platinum resistance of resistant/refractory germ-cell tumors (GCTs), but expectancy of cure remains low. New strategies are needed with new drugs and a sequential approach.
Materials and methods: Patients with relapsed poor-prognosis GCTs were scheduled to receive two cycles combining epirubicin and paclitaxel (Taxol) followed by three consecutive HD-CT supported by stem cell transplantation [one course combining cyclophosphamide, 3 g/m2 + thiotepa, 400 mg/m2, followed by two ICE regimens (ifosfamide, 10 g/m2, carboplatin, AUC 20, etoposide, 1500 mg/m2)].
Results: From March 1998 to September 2001 (median follow-up, 31.8 months), 45 patients (median age, 28 years) were enrolled in this phase II study. Twenty-two patients received the complete course. Twenty-five patients died from progression and five from toxicity. The overall response rate was 37.7%, including an 8.9% complete response rate. The median overall survival was 11.8 months. The 3-year survival and progression-free survival rate was 23.5%. The ‘Beyer’ prognostic score predicted the outcome after HD-CT.
Conclusion: Although our results warrant further studies on HD-CT in relapsed poor prognosis GCTs, patients with a Beyer score >2 did not benefit from this approach and should not be enrolled in HD-CT trials. Better selection criteria have to be fulfilled in forthcoming studies.
Key words: germ-cell tumors, high-dose chemotherapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. H. Einhorn, S. D. Williams, A. Chamness, M. J. Brames, S. M. Perkins, and R. Abonour High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors N. Engl. J. Med., July 26, 2007; 357(4): 340 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. V. Kondagunta and R. J. Motzer Chemotherapy for Advanced Germ Cell Tumors J. Clin. Oncol., December 10, 2006; 24(35): 5493 - 5502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Pedrazzoli, J. Ledermann, J-P Lotz, S Leyvraz, M Aglietta, G Rosti, K. Champion, S Secondino, F Selle, N Ketterer, et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults Ann. Onc., October 1, 2006; 17(10): 1479 - 1488. [Abstract] [Full Text] [PDF]
|
|